Sugi Predict

Sugi Predict / Targets / KCNK5

KCNK5

Potassium channel subfamily K member 5 · O95279 · KCNK5 on Sugi Atlas →

414 patent compounds predicted against KCNK5, 259 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL498641 SCHEMBL498641 1.00 1/20
SCHEMBL4231221 SCHEMBL4231221 0.85 1/20
SCHEMBL12434336 SCHEMBL12434336 0.84 1/20
SCHEMBL12434391 SCHEMBL12434391 0.83 1/20
SCHEMBL4231667 SCHEMBL4231667 0.79 1/20
SCHEMBL4234451 SCHEMBL4234451 0.79 1/20
SCHEMBL12434396 SCHEMBL12434396 0.79 1/20
SCHEMBL4234905 SCHEMBL4234905 0.78 1/20
SCHEMBL12434045 SCHEMBL12434045 0.78 1/20
SCHEMBL726080 SCHEMBL726080 0.77 1/20
SCHEMBL13789620 SCHEMBL13789620 0.74 1/20
SCHEMBL12434450 SCHEMBL12434450 0.73 1/20
SCHEMBL13789610 SCHEMBL13789610 0.71 1/20
SCHEMBL12434333 SCHEMBL12434333 0.69 1/20
SCHEMBL12434042 SCHEMBL12434042 0.68 1/20
SCHEMBL12434334 SCHEMBL12434334 0.68 1/20
SCHEMBL12434091 SCHEMBL12434091 0.67 1/20
SCHEMBL13789469 SCHEMBL13789469 0.67 1/20
SCHEMBL12434454 SCHEMBL12434454 0.67 1/20
SCHEMBL2634370 SCHEMBL2634370 0.66 1/20

Clinical trials — most relevant to KCNK5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery PHASE4RECRUITING
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation PHASE4RECRUITING
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients PHASE2COMPLETED
N-of-1 in ATS and MEPPC PHASE2NOT_YET_RECRUITING
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy PHASE1/PHASE2RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss PHASE2COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK PHASE1COMPLETED
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 PHASE1RECRUITING
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet PHASE1NOT_YET_RECRUITING
Peripheral KV7 Activation for Pain Relief EARLY_PHASE1COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Characteristics of Andersen-Tawil Syndrome nanCOMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats nanCOMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats nanCOMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy nanUNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias nanRECRUITING
The Natural History of TRPV4 Neuropathy nanRECRUITING
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk nanCOMPLETED
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development nanCOMPLETED
Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery nanRECRUITING
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNK5 binder may also engage these)

ProteinNameSimilarity
KCNQ2 Potassium voltage-gated channel subfamily KQT member 2 0.990 landscape →
Q95167 — 0.988 Q95167 →
O88943 — 0.988 O88943 →
Q9Z351 — 0.987 Q9Z351 →
A6H8H5 — 0.987 A6H8H5 →
Q9JK97 — 0.987 Q9JK97 →
O97531 — 0.987 O97531 →
Q8K3F6 — 0.987 Q8K3F6 →
O88944 — 0.987 O88944 →
Q63099 — 0.986 Q63099 →
Q9TTJ7 — 0.986 Q9TTJ7 →
Q9JL58 — 0.986 Q9JL58 →
Q03717 — 0.985 Q03717 →
Q4ZHA6 — 0.985 Q4ZHA6 →
Q9JK96 — 0.984 Q9JK96 →
Q8BUW1 — 0.984 Q8BUW1 →
Q60603 — 0.984 Q60603 →
KCNB1 Potassium voltage-gated channel subfamily B member 1 0.983 landscape →
KCNK10 Potassium channel subfamily K member 10 0.983 landscape →
P97414 — 0.982 P97414 →
Q920E3 — 0.982 Q920E3 →
Q8NCM2 — 0.982 Q8NCM2 →
KCNQ5 Potassium voltage-gated channel subfamily KQT member 5 0.982 landscape →
Q0P5A0 — 0.982 Q0P5A0 →
KCNQ4 Potassium voltage-gated channel subfamily KQT member 4 0.982 landscape →
P58126 — 0.982 P58126 →
KCNB2 Potassium voltage-gated channel subfamily B member 2 0.981 landscape →
O70344 — 0.981 O70344 →
Q9JIS4 — 0.981 Q9JIS4 →
SCN5A Sodium channel protein type 5 subunit alpha 0.981 landscape →